In Section C, participants will receive ABBV-744 and oral navitoclax. In Segment D, contributors will acquire ABBV-744 and ruxolitinib. Contributors will get treatment right until illness progression or even the participants are unable to tolerate the study drugs. - "Our study discovered the vital role on the KLF16/MYC regulatory axis https://napoleond444zms9.wikibriefing.com/user